FrancophonIA/ELRC3.0 huggingface dataset:
English: Isentress 600 mg film-coated tablets is used to treat adults and paediatric patients weighing at least 40 kg who are infected by HIV.
Croatian: Isentress 600 mg filmom obložene tablete primjenjuju se za liječenje odraslih i pedijatrijskih bolesnika tjelesne težine od najmanje 40 kg koji su zaraženi HIV-om.
English: • Isentress chewable tablets are not recommended in pregnancy because they have not been studied in pregnant women.
Croatian: • Primjena Isentress tableta za žvakanje u trudnoći se ne preporučuje jer nije ispitana u trudnica.
English: Following administration of an oral dose of radiolabeled raltegravir, approximately 51 and 32 % of the dose was excreted in faeces and urine, respectively.
Croatian: Nakon primjene oralne doze raltegravira označenog radioizotopom oko 51% doze izlučilo se fecesom, a oko 32% urinom.
English: Raltegravir was administered with an optimised background regimen.
Croatian: Raltegravir se primjenjivao s optimiziranom osnovnom terapijom.
English: In some patients with advanced HIV infection and a history of opportunistic infection, signs and symptoms of inflammation from previous infections may occur soon after anti-HIV treatment is started.
Croatian: U nekih bolesnika s uznapredovalom HIV infekcijom koji su već imali oportunističke infekcije mogu se ubrzo nakon početka primjene lijeka protiv HIV-a pojaviti znakovi i simptomi upale od prijašnjih infekcija.
English: In HIV-infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Croatian: U bolesnika inficiranih virusom HIV-a s teškim imunološkim deficitom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke patogene te uzrokovati ozbiljna klinička stanja ili pogoršanje simptoma.
English: • Keep the bottle tightly closed, with the desiccant in order to protect from moisture.
Croatian: • Bocu čuvati čvrsto zatvorenu, sa sredstvom za sušenje radi zaštite od vlage.
English: Raltegravir 400 mg twice daily + OBT (N = 462)
Croatian: Raltegravir 400 mg dvaput na dan + OBT (N=462)
English: Results 48-week and 240-week analyses
Croatian: Rezultati analiza 48. i 240. tjedna
English: 500 cells/mm
Croatian: 500 stanica/mm
English: Raltegravir Pharmacokinetic Parameters IMPAACT P1066 Following Administration of Doses in Section 4.2
Croatian: Farmakokinetički parametri raltegravira u ispitivanju IMPAACT P1066 nakon primjena doza navedenih u dijelu 4.2
English: 2 blue (10 mL) syringes
Croatian: 2 plave (10 ml) štrcaljke
English: In drug interaction studies performed using raltegravir 400 mg twice daily, raltegravir did not have a clinically meaningful effect on the pharmacokinetics of etravirine, maraviroc, tenofovir disoproxil fumarate, hormonal contraceptives, methadone, midazolam or boceprevir.
Croatian: U ispitivanjima interakcija s raltegravirom u dozi od 400 mg dvaput na dan raltegravir nije imao klinički značajan učinak na farmakokinetiku etravirina, maraviroka, tenofovirdizoproksilfumarata, hormonskih kontraceptiva, metadona, midazolama ili boceprevira.
English: Each single-use sachet contains 100 mg of raltegravir which is to be suspended in 10 mL of water giving a final concentration of 10 mg per mL (see section 6.6).
Croatian: Jedna vrećica za jednokratnu primjenu sadrži 100 mg raltegravira koji se mora suspendirati u 10 ml vode kako bi se dobila konačna koncentracija od 10 mg po ml (vidjeti dio 6.6).
English: Excipient with known effect Each tablet contains 26.06 mg lactose (as monohydrate).
Croatian: Pomoćna tvar s poznatim učinkom Jedna tableta sadrži 26,06 mg laktoze (u obliku hidrata).
English: • loss of memory; pain in the hand due to nerve compression; disturbance in attention; dizziness with rapid changes in posture; abnormal taste; increased sleepiness; lack of energy; forgetfulness; migraine headache; loss of feeling, numbness or weakness of the arms and/or legs; tingling; sleepiness; tension headache; tremors; poor quality sleep
Croatian: • gubitak pamćenja; bol u šaci zbog pritiska na živac; poremećaj pažnje; omaglica kod naglih promjena položaja tijela; promijenjen osjet okusa; povećana pospanost; nedostatak energije; zaboravljivost; migrena; smanjena osjetljivost, utrnulost ili slabost u rukama i/ili nogama; trnci; pospanost; tenzijska glavobolja; nevoljno drhtanje (tremor); loša kvaliteta sna
English: In adults, there were no clinically important pharmacokinetic differences between patients with severe renal insufficiency and healthy subjects (see section 4.2).
Croatian: U odraslih nije bilo klinički značajne razlike u farmakokinetici lijeka između bolesnika s teškom insuficijencijom bubrega i zdravih ispitanika (vidjeti dio 4.2).
English: Pull back the plunger.
Croatian: Počnite povlačiti klip.
English: Adults The recommended dosage is 400 mg (one tablet) twice daily.
Croatian: Odrasli Preporučena doza je 400 mg (jedna tableta) dvaput na dan.
English: tenofovir AUC  10 % tenofovir C24hr  13 % tenofovir Cmax ↓ 23 %
Croatian: tenofovir AUC  10% tenofovir C24h  13% tenofovir Cmax ↓ 23%
English: One pack size is available: 1 carton with 60 sachets, two 10 mL syringes, two 3 mL syringes, two 1 mL syringes, two mixing cups, this package leaflet and booklet with instructions for use.
Croatian: Dostupna je jedna veličina pakiranja: 1 kutija sa 60 vrećica, dvije štrcaljke od 10 ml, dvije štrcaljke od 3 ml, dvije štrcaljke od 1 ml, 2 čaše za miješanje, ovom uputom o lijeku i knjižicom s uputama za primjenu.
English: Co-administration of raltegravir 1,200 mg once daily and tipranavir/ritonavir is not recommended.
Croatian: Istodobna primjena raltegravira u dozi od 1200 mg jedanput na dan i tipranavira/ritonavira se ne preporučuje.
English: No evidence of mutagenicity or genotoxicity was observed in in vitro microbial mutagenesis (Ames) tests, in vitro alkaline elution assays for DNA breakage and in vitro and in vivo chromosomal aberration studies.
Croatian: U in vitro testovima mutageneze na mikroorganizmima (Amesov test), in vitro testovima alkalne elucije radi utvrđivanja oštećenja DNK te in vitro i in vivo ispitivanjima kromosomskih aberacija nisu otkriveni znakovi mutagenosti ili genotoksičnosti.
English: In addition, tenofovir disoproxil fumarate may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 3).
Croatian: Nadalje, tenofovirdizoproksilfumarat može povisiti koncentraciju raltegravira u plazmi, ali nije poznat mehanizam ovog učinka (vidjeti Tablicu 3).
English: In addition, relative to the raltegravir 400 mg formulation the raltegravir 600 mg formulation used in the 1,200 mg (2 x 600 mg) once daily dosing regimen has higher relative bioavailability (by 21 to 66%).
Croatian: Osim toga, formulacija raltegravira od 600 mg koja se koristi u režimu doziranja od 1200 mg (2 x 600 mg) jedanput na dan ima veću relativnu bioraspoloživost (za 21 do 66%) nego formulacija raltegravira od 400 mg.
English: In addition, tenofovir disoproxil fumarate may increase plasma levels of raltegravir, however, the mechanism for this effect is unknown (see Table 1).
Croatian: Nadalje, tenofovirdizoproksilfumarat može povisiti koncentraciju raltegravira u plazmi, ali nije poznat mehanizam ovog učinka (vidjeti Tablicu 1).
English: Each single-use sachet contains 100 mg of raltegravir which is to be suspended in 10 mL of water giving a final concentration of 10 mg per mL.
Croatian: Jedna vrećica za jednokratnu primjenu sadrži 100 mg raltegravira koji se mora suspendirati u 10 ml vode kako bi se dobila konačna koncentracija od 10 mg po ml.
English: Baseline Characteristics and Efficacy Outcomes at Weeks 24 and 48 from IMPAACT P1066 (4 weeks to less than 2 years of age)
Croatian: Početne karakteristike bolesnika i ishodi djelotvornosti u 24. i 48. tjednu iz ispitivanja IMPAACT P1066 (dob: 4 tjedna do manje od 2 godine)
English: Raltegravir 400 mg twice daily may be administered with or without food.
Croatian: Raltegravir u dozi od 400 mg dvaput na dan može se primijeniti s hranom ili bez nje.
English: Co-administration of raltegravir with aluminium and/or magnesium antacids is not recommended (see section 4.5).
Croatian: Istodobna primjena raltegravira s antacidima koji sadrže aluminij i/ili magnezij se ne preporučuje (vidjeti dio 4.5).
English: Therefore, when raltegravir is co-administered with calcium carbonate containing antacids no dose adjustment is required.
Croatian: Stoga pri istodobnoj primjeni raltegravira i antacida koji sadrže kalcijev karbonat nije potrebno prilagođavati dozu.
English: • decreased white blood cell count; decreased count of platelets in blood (a kind of cell that helps blood clot); blood test showing reduced kidney function; high blood sugar level; increased muscle enzyme in blood; sugar present in urine; red blood cells present in urine; weight gain; increase in waist size; decreased blood protein (albumin); increase in time for blood to clot
Croatian: • smanjen broj bijelih krvnih stanica; smanjen broj krvnih pločica (stanice koje pomažu zgrušavanju krvi); rezultati krvnih pretraga koji ukazuju na smanjenu funkciju bubrega; visoke razine šećera u krvi; povišene vrijednosti enzima iz mišića u krvi; šećer u mokraći; crvene krvne stanice u mokraći; porast tjelesne težine; povećanje opsega struka; snižene vrijednosti bjelančevina (albumina) u krvi; produljeno vrijeme zgrušavanja krvi.
English: What you need to know before you take Isentress How to take Isentress
Croatian: Što morate znati prije nego počnete uzimati Isentress Kako uzimati Isentress
English: Inhibition of integrase prevents the covalent insertion, or integration, of the HIV genome into the host cell genome.
Croatian: Inhibicija integraze sprječava kovalentno umetanje, odnosno integraciju, genoma HIV-a u genom stanice domaćina.
English: 1 to 4 Weeks - Twice daily dosing
Croatian: Dob od 1 do 4 tjedana - primjena dvaput na dan od 2 do manje od 3
English: Co-administration of raltegravir with medicinal products that are known to be potent UGT1A1 inhibitors (e.g., atazanavir) may increase plasma levels of raltegravir.
Croatian: Istodobna primjena raltegravira s lijekovima za koje se zna da su potentni inhibitori UGT1A1 (npr. atazanavir) može povisiti koncentraciju raltegravira u plazmi.
English: Two pack sizes are available: 1 bottle with 60 tablets, and a multipack containing 180 (3 bottles of 60) tablets.
Croatian: Dostupne su dvije veličine pakiranja: 1 boca sa 60 tableta i višestruko pakiranje sa 180 (3 boce sa 60) tableta.
English: In vitro studies indicate that raltegravir is not a substrate of cytochrome P450 (CYP) enzymes, does not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP3A, does not inhibit UDP glucuronosyltransferases (UGTs) 1A1 and 2B7, does not induce CYP3A4 and does not inhibit P-glycoprotein-mediated transport.
Croatian: Ispitivanja in vitro pokazuju da raltegravir nije supstrat enzima citokroma P450 (CYP), ne inhibira CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 ili CYP3A, ne inhibira UDP glukuronoziltransferaze (UGT) 1A1 i 2B7, ne inducira CYP3A4 niti inhibira transport posredovan P-glikoproteinom.
English: Geometric Mean (% CV Ctrough (ng/mL)
Croatian: Geometrijska srednja vrijednost (% CV Ctrough (ng/ml)
English: Use with caution in patients who have had myopathy or rhabdomyolysis in the past or have any predisposing issues including other medicinal products associated with these conditions (see section 4.4).
Croatian: Lijek treba primjenjivati uz oprez u bolesnika koji su imali miopatiju ili rabdomiolizu ili imaju bilo koji od predisponirajućih faktora, uključujući druge lijekove čija je primjena povezana s tim stanjima (vidjeti dio 4.4).
English: In general, the safety profile of raltegravir in patients with hepatitis B and/or hepatitis C virus co-infection was similar to that in patients without hepatitis B and/or hepatitis C virus co-infection, although the rates of AST and ALT abnormalities were somewhat higher in the subgroup co-infected with hepatitis B and/or hepatitis C virus.
Croatian: Sigurnosni profil raltegravira općenito je bio sličan u bolesnika istodobno inficiranih virusom hepatitisa B i/ili hepatitisa C i u bolesnika koji nisu istodobno inficirani virusom hepatitisa B i/ili hepatitisa C, premda su odstupanja vrijednosti AST-a i ALT-a bila nešto viša u podskupini bolesnika s istodobnom infekcijom virusom hepatitisa B i/ili hepatitisa C.
English: These findings can be extended to raltegravir 1,200 mg once daily and no dosage adjustment is required for these agents.
Croatian: Ovi nalazi mogu se primijeniti i na raltegravir u dozi od 1200 mg jedanput na dan te nije potrebno prilagođavati dozu ovih lijekova.
English: Keep the bottle tightly closed, with the desiccant in order to protect from moisture.
Croatian: Bocu čuvati čvrsto zatvorenu, sa sredstvom za sušenje radi zaštite od vlage.
English: Raltegravir Pharmacokinetic Parameters IMPAACT P1066 Following Administration of Doses in Section 4.2 (excluding neonates)
Croatian: Farmakokinetički parametri raltegravira u ispitivanju IMPAACT P1066 nakon primjena doza navedenih u dijelu 4.2 (izuzev novorođenčadi)
English: A moderate amount of data on pregnant women (between 300 - 1,000 pregnancy outcomes from first trimester exposure) indicate no malformative or feto/neonatal toxicity of raltegravir 400 mg twice daily.
Croatian: Umjerena količina podataka o trudnicama (između 300 i 1000 ishoda trudnoće uz izloženost tijekom prvog tromjesečja) ne ukazuje na malformativnu ili feto/neonatalnu toksičnost raltegravira primijenjenog u dozi od 400 mg dvaput na dan.
English: Raltegravir chewable tablets should be used during pregnancy only if the expected benefit justifies the potential risk to the foetus.
Croatian: Raltegravir tablete za žvakanje smiju se primjenjivati tijekom trudnoće samo ako očekivana korist opravdava potencijalni rizik za fetus.
English: Scheduled appointments for the patient should be kept because the ISENTRESS dosage should be adjusted as the child grows.
Croatian: Treba se pridržavati dogovorenih kontrolnih pregleda jer se doza lijeka ISENTRESS mora prilagođavati kako dijete raste.
English: 492 cells/mm
Croatian: 492 stanice/mm
English: Additional considerations
Croatian: Dodatne napomene
English: Excipient with known effect Each 600 mg tablet contains 5.72 mg lactose (as monohydrate).
Croatian: Pomoćna tvar s poznatim učinkom Jedna tableta od 600 mg sadrži 5,72 mg laktoze (u obliku hidrata).
English: emtricitabine and tenofovir disoproxil fumarate (raltegravir 1,200 mg (2 x 600 mg) Once Daily)
Croatian: emtricitabin i tenofovirdizoproksilfumarat (raltegravir 1200 mg (2 x 600 mg) jedanput na dan)
English: From the clinical trials, a large proportion of patients used atazanavir and / or tenofovir disoproxil fumarate, both agents that result in increases in raltegravir plasma levels, in the optimised background regimens.
Croatian: Iz kliničkih ispitivanja velik je udio bolesnika u sklopu optimizirane osnovne terapije primao atazanavir i/ili tenofovirdizoproksilfumarat, oba lijeka koji povisuju koncentraciju raltegravira u plazmi.
English: • feeling dizzy; headache
Croatian: • omaglica; glavobolja
English: • increased liver blood tests; abnormal white blood cells; increased fat levels in blood; increased level of enzyme from salivary glands or pancreas
Croatian: • povišene vrijednosti testova jetrene funkcije; promjene na bijelim krvnim stanicama; povišene razine masnoća u krvi; povišene vrijednosti enzima iz žlijezda slinovnica ili gušterače.
English: This medicine can be taken with or without food or drink.
Croatian: Ovaj lijek može se uzimati s hranom i pićem ili bez njih.
English: If co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir (400 mg twice daily) can be considered.
Croatian: Ako je istodobna primjena s rifampicinom neizbježna, može se razmotriti udvostručenje doze raltegravira (400 mg dvaput na dan).
English: Co-administration of raltegravir (1,200 mg once daily) is not recommended.
Croatian: Istodobna primjena raltegravira (1200 mg jedanput na dan) se ne preporučuje.
English: Infants and toddlers 4 weeks to less than 2 years of age IMPAACT P1066 also enrolled HIV-infected, infants and toddlers 4 weeks to less than 2 years of age who had received prior antiretroviral therapy either as prophylaxis for prevention of mother to child transmission (PMTCT) and/or as combination antiretroviral therapy for treatment of HIV infection.
Croatian: U ispitivanje IMPAACT P1066 također su bila uključena dojenčad i mala djeca u dobi od 4 tjedna do manje od 2 godine inficirana HIV-om, koja su prethodno primala antiretrovirusnu terapiju ili kao profilaksu za sprječavanje prijenosa s majke na dijete i/ili u sklopu kombinirane antiretrovirusne terapije za liječenje HIV infekcije.
English: Isentress contains the active substance raltegravir.
Croatian: Isentress sadrži djelatnu tvar raltegravir.
English: 2 green (3 mL) syringes
Croatian: 2 zelene (3 ml) štrcaljke
English: The treatment difference (raltegravir 1,200 mg once daily-raltegravir 400 mg twice daily) was 1.5 % with an associated 95 % CI of (-4.4, 7.3).
Croatian: Razlika između liječenja (raltegravir 1200 mg jedanput na dan - raltegravir 400 mg dvaput na dan) iznosila je 1,5% uz pripadajući 95%-tni CI (-4,4; 7,3).
English: 3 x 100 mg twice daily The weight-based dosing recommendation for the chewable tablet is based on approximately 6 mg/kg/dose twice daily (see section 5.2).
Croatian: 3 x 100 mg dvaput na dan Preporuke za doziranje tableta za žvakanje prema tjelesnoj težini temelje se na približnoj dozi od 6 mg/kg dvaput na dan (vidjeti dio 5.2).
English: Patients with rare hereditary problems of fructose intolerance glucosegalactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Croatian: Bolesnici s rijetkim nasljednim poremećajima nepodnošenja fruktoze, malapsorpcijom glukoze i galaktoze ili saharazaizomaltaza insuficijencijom ne bi smjeli uzimati ovaj lijek.
English: The maximum dose of the chewable tablet is 300 mg twice daily.
Croatian: Najviša doza tableta za žvakanje je 300 mg dvaput na dan.
English: Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
Croatian: Obavijestite svog liječnika ili ljekarnika ako uzimate, nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove.
English: High density polyethylene (HDPE) bottle with a child-resistant polypropylene closure, induction seal and silica gel desiccant: 60 tablets.
Croatian: Boca od polietilena visoke gustoće (HDPE) s polipropilenskim sigurnosnim zatvaračem za djecu, zalijepljenim zaštitnim pokrovom i silika gelom kao sredstvom za sušenje: 60 tableta.
English: At Week 240, the treatment difference (raltegravir - efavirenz) was 9.5 % with an associated 95 % CI of (1.7, 17.3).
Croatian: U 240. tjednu razlika u odgovoru na liječenje (raltegravir - efavirenz) iznosila je 9,5%,uz pripadajući 95%-tni CI od (1,7; 17,3).
English: Isentress chewable tablets contain fructose and sorbitol If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.
Croatian: Isentress tablete za žvakanje sadrže fruktozu i sorbitol Ako Vam je liječnik rekao da ne podnosite neke šećere, savjetujte se s liječnikom prije uzimanja ovog lijeka.
English: 60 chewable tablets
Croatian: 60 tableta za žvakanje
English: If co-administration with rifampicin is unavoidable, a doubling of the dose of raltegravir can be considered (see section 4.4).
Croatian: Ako je istodobna primjena s rifampicinom neizbježna, može se razmotriti udvostručenje doze raltegravira (vidjeti dio 4.4).
English: Uncommon alanine aminotransferase increased, atypical lymphocytes, aspartate aminotransferase increased, blood triglycerides increased, lipase increased, blood pancreatic amylase increased absolute neutrophil count decreased, alkaline phosphatase increased, blood albumin decreased, blood amylase increased, blood bilirubin increased, blood cholesterol increased, blood creatinine increased, blood glucose increased, blood urea nitrogen increased, creatine phosphokinase increased, fasting blood glucose increased, glucose urine present, high density lipoprotein increased, international normalised ratio increased, low density lipoprotein increased, platelet count decreased, red blood cells urine positive, waist circumference increased, weight increased, white blood cell count decreased
Croatian: Pretrage često manje često povišena alanin aminotransferaza, atipični limfociti, povišena aspartat aminotransferaza, povišeni trigliceridi u krvi, povišene lipaze, povišena pankreatična amilaza u krvi smanjen apsolutni broj neutrofila, povišena alkalna fosfataza, sniženi albumin u krvi, povišena amilaza u krvi, povišen bilirubin u krvi, povišen kolesterol u krvi, povišen kreatinin u krvi, povišene vrijednosti glukoze u krvi, povišene vrijednosti dušika iz ureje u krvi, povišene vrijednosti kreatin fosfokinaze, povišene vrijednosti glukoze natašte, glukoza u urinu, povišene vrijednosti lipoproteina visoke gustoće, povećan međunarodni normalizirani omjer (INR), povišene vrijednosti lipoproteina niske gustoće, smanjen broj trombocita, eritrociti u urinu, povećan opseg struka, porast tjelesne težine, smanjen broj bijelih krvnih stanica
English: Infections and infestations Uncommon genital herpes, folliculitis, gastroenteritis, herpes simplex, herpes virus infection, herpes zoster, influenza, lymph node abscess, molluscum contagiosum, nasopharyngitis, upper respiratory tract infection
Croatian: Infekcije i infestacije manje često genitalni herpes, folikulitis, gastroenteritis, herpes simplex, infekcija virusom herpesa, herpes zoster, influenca, apsces limfnih čvorova, mollusca contagiosa, nazofaringitis, infekcije gornjeg respiratornog trakta
English: • antacids (an agent that counteracts or neutralises the acid in the stomach to relieve indigestion and heartburn).
Croatian: • Antacide (lijekove koji suzbijaju ili neutraliziraju kiselinu u želucu radi ublažavanja probavnih tegoba i žgaravice).
English: • antacids (an agent that counteracts or neutralises the acid in the stomach to relieve indigestion and heartburn)
Croatian: • antacide (lijekove koji suzbijaju ili neutraliziraju kiselinu u želucu radi ublažavanja probavnih tegoba i žgaravice)
English: Add Isentress to the cup
Croatian: 6. korak: Dodajte Isentress u čašu
English: There are no data to guide co-administration of raltegravir with rifampicin in patients below 18 years of age (see section 4.4).
Croatian: Nema podataka na temelju kojih bi se mogle dati smjernice za istodobnu primjenu raltegravira s rifampicinom u bolesnika mlađih od 18 godina (vidjeti dio 4.4).
English: PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
Croatian: PODACI KOJI SE MORAJU NALAZITI NA MALOM UNUTARNJEM PAKIRANJU
English: Raltegravir AUC and Cmax increase dose proportionally over the dose range 100 mg to 1,600 mg. Raltegravir C12 hr increases dose proportionally over the dose range of 100 to 800 mg and increases slightly less than dose proportionally over the dose range 100 mg to 1,600 mg.
Croatian: Proporcionalno dozi povećava se i C12h raltegravira u rasponu doza od 100 mg do 800 mg, dok je u rasponu doza od 100 mg do 1600 mg taj porast nešto manji od proporcionalnog.
English: Randomisation was stratified by screening HIV RNA level (≤ 100,000 copies/mL; and > 100,000 copies/mL) and by hepatitis B or C status (positive or negative).
Croatian: Randomizacija je bila stratificirana probirom na temelju razine HIV-RNK (≤ 100 000 kopija/ml i > 100 000 kopija/ml) i statusa hepatitisa B ili C (pozitivan ili negativan).
English: Co-administration of raltegravir (400 mg twice daily and 1,200 mg once daily) with aluminium and/or magnesium containing antacids is not recommended.
Croatian: Istodobna primjena raltegravira (400 mg dvaput na dan i 1200 mg jedanput na dan) s antacidima koji sadrže aluminij i/ili magnezij se ne preporučuje.